603 related articles for article (PubMed ID: 17101852)
1. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
Thanikachalam S; Manchanda SC
Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
[TBL] [Abstract][Full Text] [Related]
3. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
[TBL] [Abstract][Full Text] [Related]
4. Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity.
Civelli M; Cardinale D; Martinoni A; Lamantia G; Colombo N; Colombo A; Gandini S; Martinelli G; Fiorentini C; Cipolla CM
Int J Cardiol; 2006 Jul; 111(1):120-6. PubMed ID: 16242796
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction.
Guazzi M; Melzi G; Marenzi GC; Agostoni P
Clin Pharmacol Ther; 1999 Mar; 65(3):319-27. PubMed ID: 10096264
[TBL] [Abstract][Full Text] [Related]
6. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin.
de Bree E; van Ruth S; Schotborgh CE; Baas P; Zoetmulder FA
Ann Surg Oncol; 2007 Oct; 14(10):3019-26. PubMed ID: 17638057
[TBL] [Abstract][Full Text] [Related]
7. Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?
Granger CB
Circulation; 2006 Dec; 114(23):2432-3. PubMed ID: 17146002
[No Abstract] [Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction.
Maia LN; Nicolau JC; Vítola JV; Santos M; Brandi JM; Joaquim MR; Baggi JM; Cordeiro JA; de Godoy MF
Am Heart J; 2003 Jun; 145(6):E21. PubMed ID: 12796769
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
de Denus S; Tardif JC; White M; Bourassa MG; Racine N; Levesque S; Ducharme A
Am Heart J; 2006 Oct; 152(4):705-12. PubMed ID: 16996842
[TBL] [Abstract][Full Text] [Related]
11. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).
Bosch X; Rovira M; Sitges M; Domènech A; Ortiz-Pérez JT; de Caralt TM; Morales-Ruiz M; Perea RJ; Monzó M; Esteve J
J Am Coll Cardiol; 2013 Jun; 61(23):2355-62. PubMed ID: 23583763
[TBL] [Abstract][Full Text] [Related]
12. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
[TBL] [Abstract][Full Text] [Related]
13. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
Parker AB; Yusuf S; Naylor CD
Am Heart J; 2002 Dec; 144(6):941-7. PubMed ID: 12486418
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.
Ramaciotti C; Heistein LC; Coursey M; Lemler MS; Eapen RS; Iannaccone ST; Scott WA
Am J Cardiol; 2006 Sep; 98(6):825-7. PubMed ID: 16950195
[TBL] [Abstract][Full Text] [Related]
15. Letter by Hammoud et al regarding article "Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition".
Hammoud R; Vaccari CS; Khan BV
Circulation; 2007 Jun; 115(24):e637; author reply e638. PubMed ID: 17576877
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS).
Chockalingam A; Venkatesan S; Subramaniam T; Jagannathan V; Elangovan S; Alagesan R; Gnanavelu G; Dorairajan S; Krishna BP; Chockalingam V;
Am Heart J; 2004 Apr; 147(4):E19. PubMed ID: 15077102
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
[TBL] [Abstract][Full Text] [Related]
18. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
Rouleau JL; Warnica WJ; Baillot R; Block PJ; Chocron S; Johnstone D; Myers MG; Calciu CD; Dalle-Ave S; Martineau P; Mormont C; van Gilst WH;
Circulation; 2008 Jan; 117(1):24-31. PubMed ID: 18071079
[TBL] [Abstract][Full Text] [Related]
19. Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
Silber JH; Cnaan A; Clark BJ; Paridon SM; Chin AJ; Rychik J; Hogarty AN; Cohen MI; Barber G; Rutkowsky M; Kimball TR; Delaat C; Steinherz LJ; Zhao H; Tartaglione MR
Am Heart J; 2001 Oct; 142(4):577-85. PubMed ID: 11579345
[TBL] [Abstract][Full Text] [Related]
20. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.
Willenheimer R; van Veldhuisen DJ; Silke B; Erdmann E; Follath F; Krum H; Ponikowski P; Skene A; van de Ven L; Verkenne P; Lechat P;
Circulation; 2005 Oct; 112(16):2426-35. PubMed ID: 16143696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
